2052969-18-1
Chemical Structure
Upacicalcet sodium
Synonym(s): SK-1403; AJT240; PLS240
- CAS No.: 2052969-18-1
- Formula:C11H13ClN3NaO6S
- Molecular Weight:373.75
IUPAC Name: sodium (S)-2-amino-3-(3-(3-chloro-2-methyl-5-sulfophenyl)ureido)propanoate
InChIKey: KUQQRUUFBPFDOW-QRPNPIFTSA-M
SMILES: O=C(NC[C@H](N)C(O[Na])=O)NC1=CC(S(=O)(O)=O)=CC(Cl)=C1C
Biological Activity: Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Upacicalcet sodium | 99.91% | Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Upacicalcet sodium (Standard) | ≥98% | Upacicalcet sodium (Standard) is the analytical standard of Upacicalcet (sodium) (HY-109106A). This product is intended for research and analytical applications. Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic Kidney disease (CKd). Upacicalcet sodium is useful for studying SHPT. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Goto M, et al. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo. Eur J Pharmacol. 2023 Oct 5;956:175936. [Content Brief]
- [2]. Sato H, et al. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model. Bone. 2023 Feb;167:116613. [Content Brief]
